Exalenz Bioscience's BreathID platform detects portal hypertension in NASH patients — 4 insights

Exalenz Bioscience BreathID breath test platform can accurately detect clinically significant portal hypertension in non-alcoholic steatohepatitis patients with compensated advanced chronic liver disease.

Researchers studied 257 NASH patients who participated in two parallel studies, comparing the use of BreathID C-methacetin breath test to a control measurement.

Current methods for detecting clinically significant portal hypertension are invasive and complex.

Here's what you should know:

1. The breath test had 88 percent sensitivity and 85 percent specificity.

2. Approximately 62.3 percent of the patient group had clinically significant portal hypertension.

3. The company is encouraged by the results of the trial and believes its breath test could be modified to fit a range of gastrointestinal diseases.

4. Exalenz Bioscience CEO Raffi Werner said, "[BreathID] effectively detects CSPH in NASH patients, which could give clinicians a novel noninvasive tool to improve the management of this growing, complex patient population. We have a strategy in place to bring this innovative test to market with a potential product launch in 2020."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast